Most cited papers from Tolmar (United States)

Tolmar (United States)

What are the most cited papers from Tolmar (United States)?

The most cited paper from Tolmar (United States) is "Paclitaxel-loaded redox-sensitive nanoparticles based on hyaluronic acid-vitamin E succinate conjugates for improved lung cancer treatment" (Yu Na Song, Han Cai, Tingjie Yin et al., 2018), with 98 citations. Next come "Prion Remains Infectious after Passage through Digestive System of American Crows (Corvus brachyrhynchos)" (56) and "Diethylene glycol monoethyl ether: an emerging solvent in topical dermatology products" (52).

Published TypeFieldAccess

Showing 34 of 34 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Paclitaxel-loaded redox-sensitive nanoparticles based on hyaluronic acid-vitamin E succinate conjugates for improved lung cancer treatment Yu Na Song, Han Cai, Tingjie Yin et al. · International Journal of Nanomedicine Open access	Mar 2018	98
2	Prion Remains Infectious after Passage through Digestive System of American Crows (Corvus brachyrhynchos) Kurt C. VerCauteren, John L. Pilon, Paul B. Nash et al. · PLoS ONE Open access	17 Oct 2012	56
3	Diethylene glycol monoethyl ether: an emerging solvent in topical dermatology products David W. Osborne · Journal of Cosmetic Dermatology	Dec 2011	52
4	Mechanical properties and osteogenic potential of hydroxyapatite-PLGA-collagen biomaterial for bone regeneration Didarul B. Bhuiyan, John C. Middleton, Rina Tannenbaum et al. · Journal of Biomaterials Science Polymer Edition	28 Apr 2016	36
5	New Advances and Applications in Field-Flow Fractionation Christine L Plavchak, William C. Smith, Carmen R.M. Bria et al. · Annual Review of Analytical Chemistry ReviewOpen access	26 Mar 2021	28
6	Bone regeneration from human mesenchymal stem cells on porous hydroxyapatite-PLGA-collagen bioactive polymer scaffolds Didarul B. Bhuiyan, John C. Middleton, Rina Tannenbaum et al. · Bio-Medical Materials and Engineering	22 Nov 2017	26
7	Pharmacokinetic and pharmacodynamic comparison of subcutaneous versus intramuscular leuprolide acetate formulations in male subjects Daniel R. Saltzstein, Neal D. Shore, Judd W. Moul et al. · Therapeutic Advances in Urology Open access	22 Nov 2017	25
8	Environmental Urban Noise Daniel R. Raichel · The Journal of the Acoustical Society of America	27 Aug 2003	24
9	Polymer‐delivered subcutaneous leuprolide acetate formulations achieve and maintain castrate concentrations of testosterone in four open‐label studies in patients with advanced prostate cancer Neal D. Shore, Franklin M. Chu, Judd W. Moul et al. · British Journal of Urology Open access	19 Mar 2016	19
10	Feasibility of infectious prion digestion using mild conditions and commercial subtilisin John L. Pilon, Paul B. Nash, Terry Arver et al. · Journal of Virological Methods	24 May 2009	18
11	Managing a Long and Winding Road: Estrogen Receptor–Positive Breast Cancer Michael Gnant, Nicholas C. Turner, Cristina Hernándo · American Society of Clinical Oncology Educational Book Open access	Jun 2023	15
12	The Impact of Late Luteinizing Hormone-Releasing Hormone Agonist Dosing on Testosterone Suppression in Patients with Prostate Cancer: An Analysis of United States Clinical Data E. David Crawford, Przemyslaw W. Twardowski, Raoul S. Concepcion et al. · The Journal of Urology	3 Oct 2019	14
13	The Design of Learning Software: Principles Learned from the Computer as Learning Partner Project Judith S. Stern · Journal of Science Education and Technology	Mar 2000	9
14	Subcutaneous in situ gel delivered leuprolide acetate's consistent and prolonged drug delivery maintains effective testosterone suppression independent of age and weight in men with prostate cancer Joseph Renzulli, Scott T. Tagawa, Stuart N. Atkinson et al. · BJUI Compass Open access	22 Apr 2020	6
15	High Resolution Mass Spectrometric Analysis of Vitamin B 12 Opens the Door to Structural Identification of Cobalamin Impurities Dennis Gessmann, Paul Brown, Celena M. Josephitis et al. · Analytical Chemistry	30 Sep 2025	5
16	Real-world analyses of major adverse cardiovascular events and mortality risk after androgen deprivation therapy initiation in black vs. white prostate cancer patients Judd W. Moul, Deborah M. Boldt‐Houle, Mack Roach · Prostate Cancer and Prostatic Diseases Open access	18 Apr 2025	1
17	6-month Formulations of Androgen Deprivation Therapy for Advanced Prostate Cancer: Effectiveness and Rationale for Extended Dosing Jason M. Hafron, Stuart N. Atkinson, Debbie Boldt-Houle et al. · The Open Urology & Nephrology Journal Open access	29 Jan 2024	1
18	CLO22-049: Major Adverse Cardiovascular Events Risk After Androgen Deprivation Therapy Initiation is Higher for Older Patients Lucio Gordan, Stuart N Atkinson, Deborah M. Boldt‐Houle et al. · Journal of the National Comprehensive Cancer Network	31 Mar 2022	1
19	Gel Formulation Containing Mixed Surfactant and Lipids Associating with Carboplatin Kellie A. Woll, Elie J. Schuchardt, Claire R. Willis et al. · Chemistry & Biodiversity	Dec 2011	1
20	Rucaparib – drug evaluation: a PARP inhibitor for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer Alan Haruo Bryce, Paige Nash, Anne Roessler et al. · Future Oncology Open access	18 Jun 2026	0
21	(052) Titratable Oral Testosterone Undecanoate Achieved Testosterone Level Increase of ≥500 NG/DL Across BMI Subgroups Martin M. Miner, L Yoo, Zuzanna Szmukier et al. · The Journal of Sexual Medicine Open access	Nov 2025	0
22	SAT-146 Titratable Oral Testosterone Undecanoate Effectively Achieves ≥750ng/dL Mean Testosterone Levels in Hypogonadal Men Martin M. Miner, Li Jie Helena Yoo, Zuzanna Szmukier et al. · Journal of the Endocrine Society Open access	Oct 2025	0
23	Multicenter Bioavailability Study of Long-Acting Paliperidone in Patients With Schizophrenia or Schizoaffective Disorder Thalita Martins da Silva, Débora Renz Barreto Vianna, Jessica Meulman et al. · Journal of Clinical Psychopharmacology Open access	3 Sep 2025	0
24	OR04-05 Achieving Random LH <1 IU/L Correlated with Achieving Peak LH <4 IU/L with 6-Month Subcutaneous Leuprolide Acetate Bradley Scott Miller, Debbie Boldt-Houle, Rhea Daugherty et al. · Journal of the Endocrine Society Open access	Oct 2024	0
25	(133) ORAL TESTOSTERONE UNDECANOATE QUICKLY AND EFFECTIVELY ACHIEVES SERUM TESTOSTERONE ≥ 300 NG/DL IN MOST HYPOGONADAL MEN WITHOUT DOSE TITRATIONS Martin M. Miner, Deborah M. Boldt‐Houle, Sarah Atkinson · The Journal of Sexual Medicine Open access	12 Aug 2024	0
26	1: Two years of clinical experience with six month subcutaneous leuprolide acetate for central precocious puberty Jori Matushek, Stuart N. Atkinson, Deborah M. Boldt‐Houle et al. · Journal of Pediatric Nursing	Jul 2024	0
27	9. Two and a half years of clinical experience with six month subcutaneous leuprolide acetate treatment for pubertal suppression in three boys Kristin Sabanosh, Stuart N. Atkinson, Deborah M. Boldt‐Houle et al. · Journal of Pediatric Nursing	Jul 2024	0
28	REAL-WORLD ANALYSES OF MACE RISK IN PROSTATE CANCER PATIENTS AFTER INITIATION OF LHRH AGONIST VS GNRH ANTAGONIST June Rhee, Darryl P. Leong, Stuart N. Atkinson et al. · Journal of the American College of Cardiology Open access	Apr 2024	0
29	REAL-WORLD ANALYSES OF MACE AND MORTALITY RISK IN PATIENTS WITH PROSTATE CANCER AFTER INITIATION OF LHRH AGONISTS VS. GNRH ANTAGONIST Tanya Barauskas Dorff, June‐Wha Rhee, Deborah M. Boldt‐Houle et al. · Urologic Oncology Seminars and Original Investigations	Mar 2024	0
30	6-Month subcutaneous leuprolide acetate achieved and maintained hormonal suppression in overweight children Keisha Bird, Deborah M. Boldt‐Houle, Stuart N. Atkinson · Journal of Pediatric Nursing	Sep 2023	0
31	Clinical experience with 6-month subcutaneous leuprolide acetate for central precocious puberty Jori Matushek, Deborah M. Boldt‐Houle, Stuart N. Atkinson · Journal of Pediatric Nursing	Sep 2023	0
32	THU195 6-Month Subcutaneous Leuprolide Acetate Achieved And Maintained Hormonal And Clinical Suppression In All Weight Groups Of Children With Central Precocious Puberty Bradley Scott Miller, Deborah M. Boldt‐Houle, Stuart N Atkinson · Journal of the Endocrine Society Open access	Oct 2023	0
33	CLO23-041: Cardiovascular Event Risk Following Androgen Deprivation Therapy Initiation by Personal History of Cardiovascular Events Przemyslaw W. Twardowski, Stuart N. Atkinson, Deborah M. Boldt‐Houle · Journal of the National Comprehensive Cancer Network	31 Mar 2023	0
34	6-Month Subcutaneous Leuprolide Acetate Effectively Suppresses Clinical Signs of Puberty in Children with Central Precocious Puberty Keisha Bird, Stuart N. Atkinson, Debbie Boldt-Houle · Journal of Pediatric Nursing	May 2021	0

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.